Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product ...

Shares of Molecular Partners AG Sponsored ADR (MOLN) have gained 5.7% over the past four weeks to close the last trading session at $5.55, but there could still be a solid upside left in the stock if ...

Every investor in Molecular Partners AG (VTX:MOLN) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 50% to be precise, is ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Molecular Partners develops DARPin proteins for oncology and virology, offering advantages over traditional antibodies. The company's Switch-DARPin platform offers conditional and reversible immune ...

MOLN is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of MOLN shares has decreased $0.15 since the market last closed. This is a 3.53% ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...